Protocol Ledger

NCT06975514 · Phase III · COMPLETED

Safety and Efficacy Study of YZJ-1139 Tablets in Insomnia Disorder

Interventional Phase III clinical trial protocol NCT06975514 sponsored by Shanghai Haiyan Pharmaceutical Technology Co in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-03-25 Enrollment: 61 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06975514
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)61 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06975514
Protocol FieldVerified Registry Value
NCT IdentifierNCT06975514
Consolidated Lead SponsorShanghai Haiyan Pharmaceutical Technology Co
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment61 participants (ACTUAL)
Registered Start Date2025-03-25
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI